Journal of the American Academy of Child and Adolescent Psychiatry

Last updated

Call for retraction

The group Healthy Skepticism has accused the journal of having published an article, in 2001, that misrepresented the results of an industry-sponsored clinical trial, study 329. The study examined the use of paroxetine by teenagers. [2] The trial was sponsored by, and ghostwritten on behalf of, SmithKline Beecham (now GlaxoSmithKline), and is widely regarded as having downplayed the trial's negative results. JAACAP editors have declined to retract the article, arguing that the negative results are available in the article, and that therefore there are no grounds for retraction. This claim is disputed on the basis that primary and secondary outcomes for efficacy were manipulated and safety results were obscured or omitted. Critics therefore argue that the Journal's editors have failed to uphold the scientific standards of clinical research by failing to retract a fraudulent article. [3] [4] [5] [6]

References

  1. ↑ "Journals Ranked by Impact: Pediatrics". 2014 Journal Citation Reports. Web of Science (Science ed.). Thomson Reuters. 2015.
  2. ↑ Keller, Martin; et al. (July 2001). ", 2001 "Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial"". Journal of the American Academy of Child and Adolescent Psychiatry. 40 (7): 762–772. doi:10.1097/00004583-200107000-00010. PMID   11437014.{{cite journal}}: External link in |title= (help)
  3. ↑ Isabel Heck, "Controversial Paxil paper still under fire 13 years later", The Brown Daily Herald, 2 April 2014.
  4. ↑ Newman, Melanie (2010). "The Rules of Retraction". BMJ. 341 (7785): 1246–1248. doi:10.1136/bmj.c6985. PMID   21138994.
  5. ↑ Jureidini, Jon N.; McHenry, Leemon B.; Mansfield, Peter R. (2008). "Clinical trials and drug promotion: Selective reporting of study 329". International Journal of Risk & Safety in Medicine. 20 (1–2): 73–81. doi:10.3233/JRS-2008-0426.
  6. ↑ McHenry, Leemon B.; Jureidini, Jon N. (2008). "Industry-sponsored ghostwriting in clinical trial reporting: a case study". Accountability in Research: Policies and Quality Assurance. 15 (3): 152–167. doi:10.1080/08989620802194384. PMID   18792536.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.